This is a competitive renewal application on behalf of Case Western Reserve University's (CWRU) Program and its two primary teaching hospitals, MetroHealth Medical Center (MHMC) and University Hospitals of Cleveland Ireland Cancer Center (UH). The two institutions form ONE CONSORTIUM participation in ECOG activities. The CWRU program has been continuously funded for 29 years. This request describes all the integrated activities of our institution in ECOG and allows the continuation of the following objectives and specific aims. ? ? 1. Permit the continuation of cur participation in ECOG activities, with increased accrual to all disease oriented protocols including participation in surgical and radiation therapy oriented studies. ? 2. Continue to provide follow-up. The present follow-up load consists of 535 patients. ? 3. Continue to maintain and develop additional scientific leadership in different disease committees. The Bone Marrow Transplantation Committee has been chaired, since its inception in ECOG, by Dr. Hillard Lazarus. ? 4. Expand our participation in surgically oriented studies that require blood and tumor acquisition and peri-operative adjuvant therapy. The PI is a surgical oncologist. ? 5. Develop Phase II & III studies that result from our Cancer Center Phase I trials. ? 6. Extend Group activities of Phase I & II human studies. ? 7. Develop Phase I studies, either as single institution or multi-institutional, and advance them to randomized clinical trials. ? 8. Participate in ancillary studies, chemo prevention, cancer control and quality of life protocols. ? 9. Continue to monitor terminated adjuvant studies, chaired by CWRU investigators, toxicity and prolonged survival (Ex. EST 1180 Intergroup 011-Adjuvant Therapy in Node Negative Breast Cancer). ? ? ?

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Case Western Reserve University
Schools of Medicine
United States
Zip Code
Lubner, Sam; Feng, Yang; Mulcahy, Mary et al. (2018) E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors. Oncologist 23:1006-e104
Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903
Gravis, Gwenaelle; Boher, Jean-Marie; Chen, Yu-Hui et al. (2018) Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol 73:847-855
Agarwala, Sanjiv S; Lee, Sandra J; Yip, Waiki et al. (2017) Phase III Randomized Study of 4 Weeks of High-Dose Interferon-?-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Gro J Clin Oncol 35:885-892
Kumar, Anita J; Gimotty, Phyllis A; Gelfand, Joel M et al. (2016) Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII. Am J Hematol 91:1107-1112
Ganzel, Chezi; Manola, Judith; Douer, Dan et al. (2016) Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008. J Clin Oncol 34:3544-3553
Loughran Jr, T P; Zickl, L; Olson, T L et al. (2015) Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). Leukemia 29:886-94
Fielding, Adele K; Rowe, Jacob M; Buck, Georgina et al. (2014) UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood 123:843-50
Marks, David I; Moorman, Anthony V; Chilton, Lucy et al. (2013) The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial. Haematologica 98:945-52
Averbook, Bruce J; Lee, Sandra J; Delman, Keith A et al. (2013) Pediatric melanoma: analysis of an international registry. Cancer 119:4012-9

Showing the most recent 10 out of 59 publications